Navigation Links
Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
Date:7/8/2009

on stock, will be sold for a purchase price of $1.25. The warrants will be issued in three tranches with 25% having an exercise price equal to $1.25 per share, 25% having an exercise price equal to $1.71 per share, and 50% having an exercise price equal to $2.28 per share. The warrants are redeemable by the Company, at a redemption price of $0.001 per warrant share, upon 30 days notice, if at any time, the volume weighted average price of the common stock for any 20 consecutive business days is equal to or greater than 200% of the then applicable exercise price of the warrants.

The securities have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ), a ... positive secondary findings from the first of four Phase 3 ... (SR)/bupropion SR). These data were presented in one oral ... 69th Scientific Sessions in New Orleans, Louisiana. , ...
... Mass., June 4, 2009 By applying cutting-edge techniques ... a fundamental feedback mechanism that the body uses to ... lead to a new physical, quantitative, and predictive model ... has implications for the treatment of bleeding disorders. ...
... , ST. LOUIS, June 5 /PRNewswire-FirstCall/ -- ... will present at the William Blair Growth Stock Conference on Thursday, ... Hotel in Chicago. , , This presentation will also ... investor relations section of Express Scripts web site at ...
Cached Biology Technology:Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions 2Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions 3Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions 4Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions 5Researchers solve 'bloodcurdling' mystery 2Express Scripts to Present at William Blair Growth Stock Conference 2
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
(Date:7/28/2014)... top 10 U.S. cities that have seen an increase ... frequent road closures, overwhelmed storm drains and compromised infrastructure--are ... technical report. , This nuisance flooding, caused by rising ... between 300 and 925 percent since the 1960s. , ... Changes around the United States, also finds Annapolis and ...
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Strategies identified to improve oral contraceptive success with obese women 2
... evidence a chemical referred to as hexavalent chromium, or ... is consumed in drinking water. The two-year study ... animals given hexavalent chromium developed malignant tumors. , ... cancer in humans in certain occupational settings as a ...
... has examined the mechanisms behind latent cell memory, which ... suddenly to appear. Special yeast cells for example, can ... hermaphrodite. , Researchers from the Niels Bohr Institute ... and computer simulations to examine fundamental mechanisms of cell ...
... international journal, the British Journal of Obstetrics and Gynaecology, ... increases in clinical reasons for caesareans such as complications ... to societal factors. , The research project looked at ... (more than 430,000 births) and analysed the ...
Cached Biology News:Hexavalent chromium in drinking water causes cancer in lab animals 2Latent memory of cells comes to life 2Latent memory of cells comes to life 3Study shows dramatic increase in Caesarean sections 2
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
A camera based compact unit for high speed scanning of 2D barcoded tubes in a cluster rack. This reader has been designed to read both 96 and 48 tube rack configurations and be compatible with common...
... The inductive drives of VARIOMAG Magnetic ... as motors, belts, or mechanical bearings, making ... In addition, the VARIOMAG inductive drive can ... water, dust or microorganisms. This is why ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
Biology Products: